Chris Degnan is recorded as CFO at UroGen Pharma Ltd. (URGN). The newest filing on record that lists Chris Degnan as CFO at UroGen Pharma Ltd. (URGN) is dated April 30, 2026. UroGen Pharma Ltd. reported in an 8-K filed October 9, 2024 that Chris Degnan was appointed Chief Financial Officer, effective October 8, 2024. The proxy statement of UroGen Pharma Ltd. reports total compensation of $1,053,789 for Chris Degnan in fiscal 2024, including a base salary of $115,530. Disclosed compensation is on record for 2 fiscal years. Chris Degnan has spoken on 7 earnings calls across 1 company, most recently for UroGen Pharma Ltd. on August 5, 2026. UroGen Pharma Ltd. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at UroGen Pharma Ltd. includes Elizabeth Barrett (CEO and Board Member), Arie Belldegrun (Chairman and Board Member), Dong (Don) Kim (CFO) and 7 others.
“Executive shall serve as the Company’s Chief Financial Officer. Executive’s employment with the Company shall commence on October 8, 2024 (the “Start Date”).”
UroGen Pharma Ltd. Form 8-K, filed October 9, 2024
· Read the filing
Chris Degnan on recent calls
“Total revenue was $72.5 million in the second quarter of 2026, compared with $24.2 million in the second quarter of 2025.”
“Q1 represents an important step forward as we begin to see the early commercial momentum of the story translate into meaningful revenue growth while continuing to manage our cost structure in a disciplined manner.”
“Revenues were $109.8 million for the year-end of December 31st, 2025, compared with $90.4 million in 2024. The 21% year-over-year increase was driven by the commercial launch of the story in 2025, as well as increased sales of Joe Myo.”
“So maybe just reflect again just on Q1 to your point, Tara. So just as folks may recall, we had $14 million in revenue for the story in Q4 of last year. We did expect to see an inflection once the permanent J code came into effect on January 1 of this year, and we absolutely saw that inflection.”
“JELMYTO net product revenues were $20.3 million and $18.8 million for the three months ended March 31st, 2025, and 2024 respectively. Year-over-year revenue growth of 8% was driven by underlying demand growth of 12%, partially offset by higher 340B chargebacks.”
